D-0727-2026 Class II Ongoing

Recalled by Fresenius Kabi USA, LLC — Lake Zurich, IL

FDA drug recall D-0727-2026 was initiated by Fresenius Kabi USA, LLC on Jul 16, 2026 and is designated Class II. Reason for recall: Presence of Particulate Matter: Hair was found in products The recall status is ongoing. Affected quantity: 92,600 vials.

Recall details

Product Type
Drugs
Report Date
Jul 29, 2026
Initiation Date
Jul 16, 2026
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
92,600 vials

Product description

Naropin (ropivacaine hydrochloride Injection, USP), 0.5%, 100 mg per 20 mL (5 mg per mL), Twenty-five, 20 mL Single-Dose Vials, Rx only, Fresenius Kabi, Lake Zurich, IL 60047 NDC Tray: 63323-286-23; NDC Vial: 63323-286-05

Reason for recall

Presence of Particulate Matter: Hair was found in products

Distribution pattern

Nationwide within in the USA

Code information

Lot #: 6133436, Exp. Date 10/2028

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0727-2026
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0727-2026. Report a data issue: hello@regdatalab.com.